Extended adjuvant chemotherapy in triple-negative breast cancer

Research output: Contribution to journalReview articlepeer-review


Triple-negative breast cancer (TNBC) represents a heterogeneous breast cancer subtype with a poor prognosis. The optimal adjuvant chemotherapy regimen is still unknown. Although numerous large randomized trials have established the benefit of adjuvant anthracyclines and/or taxanes in TNBC, there is no preferred regimen for these patients. There is currently no guideline. Moreover, without knowing the optimal treatment backbone, it will not be possible to evaluate whether adding agents such as platinum or other novel therapies is beneficial for TNBC patients. Furthermore, the best duration of adjuvant treatment in TNBC is still unknown. This review will focus on results of clinical trials that analyzed the benefits of extending the duration of adjuvant treatment in TNBCs with maintenance treatments. We will further discuss promising results in favor of other new agents including capecitabine, metronomic treatment, and biological drugs.

Original languageEnglish
Pages (from-to)152-158
Number of pages7
JournalBreast Care
Issue number3
Publication statusPublished - Jul 1 2017


  • Adjuvant chemotherapy
  • Biologic agents
  • Duration of adjuvant therapy
  • Metronomic chemotherapy
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Extended adjuvant chemotherapy in triple-negative breast cancer'. Together they form a unique fingerprint.

Cite this